Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Oncology Drugs in Phase II Clinical Development in UNITED KINGDOM

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Immodulon Therapeutics

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED KINGDOM United Kingdom

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ESMO 2020 Congress

              Participation Not Confirmed

              Update your events

              Immodulon, Champalimaud Foundation Team Up on ‘Difficult To Treat’ Cancers

              Contact the Supplier

              Lead Product(s): IMM-101

              Therapeutic Area: Oncology Product Name: IMM-101

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Champalimaud Foundation

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration August 03, 2020

              Details:

              Collaboration will explore clinical trials with IMM-101, in combination with other treatments, in difficult to treat cancers, with a particular focus on epithelial cancers such as pancreatic cancer and sarcoma.

              AstraZeneca PLC

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED KINGDOM United Kingdom

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ESMO 2020 Congress

              Participation Not Confirmed

              Update your events

              ENHERTU Improved Tumor Response Rate and Overall Survival in HER2-positive Metastatic Gastric Cancer in Phase II DESTINY-Gastric01 Trial

              Contact the Supplier

              Lead Product(s): Trastuzumab Deruxtecan

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 29, 2020

              Details:

              First HER2-directed medicine to show an improvement in overall survival for previously treated metastatic gastric cancer with a 41% reduction in the risk of death vs. chemotherapy.

              GlaxoSmithKline

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED KINGDOM United Kingdom

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ESMO 2020 Congress

              Participation Not Confirmed

              Update your events

              GSK Adds to Its Trove of Positive Data for Multiple Myeloma Contender as Rivals Continue to Command the Spotlight

              Contact the Supplier

              Lead Product(s): Belantamab mafodotin,Bortezomib,Dexamethasone

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 27, 2020

              Details:

              13-month update on the DREAMM-2 study shows median overall survival of 14.9 months and median duration of response of 11 months with single-agent belantamab mafodotin 2.5 mg/kg dose.

              GlaxoSmithKline

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED KINGDOM United Kingdom

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ESMO 2020 Congress

              Participation Not Confirmed

              Update your events

              GSK Highlights Scientific Innovation and Advances in its Growing Oncology Portfolio at ASCO 2020

              Contact the Supplier

              Lead Product(s): Belantamab mafodotin

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 20, 2020

              Details:

              Company will showcase presentations on investigational therapies, including belantamab mafodotin and GSK3359609, an inducible T-cell co-stimulator (ICOS) agonist for patients with recurrent or metastatic head and neck squamous cell carcinoma.

              AstraZeneca PLC

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED KINGDOM United Kingdom

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ESMO 2020 Congress

              Participation Not Confirmed

              Update your events

              Gastric-Cancer Drug Designated Breakthrough by FDA

              Contact the Supplier

              Lead Product(s): Trastuzumab Deruxtecan

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 11, 2020

              Details:

              DESTINY-Gastric01 represents the first randomised trial of Enhertu to demonstrate clinically meaningful and statistically significant results, including objective response and survival increases.

              Vaccitech Oncology

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED KINGDOM United Kingdom

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ESMO 2020 Congress

              Participation Not Confirmed

              Update your events

              Vaccitech and Oxford University Announce Promising Phase 2a Data on Prostate Cancer Immunotherapy

              Contact the Supplier

              Lead Product(s): VTP-800

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 23, 2020

              Details:

              The study demonstrated that VTP-800 is safe and showed an encouraging efficacy trend in patients with mCRPC.

              NuCana

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED KINGDOM United Kingdom

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ESMO 2020 Congress

              Participation Not Confirmed

              Update your events

              NuCana Reports Preliminary Data from Phase II Study

              Contact the Supplier

              Lead Product(s): Acelarin

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 10, 2020

              Details:

              The study compared a 500mg/m2 dose of Acelarin versus a 750mg/m2 dose of Acelarin in patients who were heavily pre-treated (at least 3 prior lines of chemotherapy).

              AstraZeneca PLC

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED KINGDOM United Kingdom

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ESMO 2020 Congress

              Participation Not Confirmed

              Update your events

              Phase II DESTINY-Gastric01 trial of Enhertu versus chemotherapy met primary endpoint

              Contact the Supplier

              Lead Product(s): Trastuzumab Deruxtecan

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 27, 2020

              Details:

              Trial met primary endpoint of objective response rate and key secondary endpoint of overall survival in patients with previously treated HER2-positive metastatic gastric cancer.

              Bicycle Therapeutics

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              United Kingdom United Kingdom

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ESMO 2020 Congress

              Participation Not Confirmed

              Update your events

              Bicycle Therapeutics and Cancer Research UK to Collaborate on Development of New Bicycle® Immuno-oncology Candidate, BT7401

              Contact the Supplier

              Lead Product(s): BT7401

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Cancer Research UK

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration January 07, 2020

              Details:

              Under the terms and conditions of the agreement, Cancer Research UK will fund and sponsor development of BT7401, a multivalent Bicycle CD137 agonist, through a Phase IIa clinical study.

              PharmaCompass__DigitalAd